Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
11:01am, Tuesday, 28'th Apr 2026
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
07:18am, Tuesday, 28'th Apr 2026
AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designe
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
02:03am, Tuesday, 28'th Apr 2026
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesit
Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly
08:15pm, Monday, 27'th Apr 2026
Eli Lilly is best known for its work in the weight loss market. The company has billion-dollar drugs in other areas.
Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch
01:21pm, Monday, 27'th Apr 2026
Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
01:15pm, Monday, 27'th Apr 2026
LLY, MRK, ABBV, BMY and BIIB are set to report this week as recent beats and key drug demand set up a pivotal Q1 earnings test for pharma giants.
Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
10:16am, Monday, 27'th Apr 2026
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of
As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst
09:48am, Monday, 27'th Apr 2026
Eli Lilly's Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth.
Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion
07:51am, Monday, 27'th Apr 2026
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker's blood-cancer portfolio.
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
07:41am, Monday, 27'th Apr 2026
Eli Lilly (LLY, Financials) announced it would buy privately held Ajax Therapeutics for up to $2.3 billion in cash to bolster its pipeline in blood cancer thera
Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
06:55am, Monday, 27'th Apr 2026
Eli Lilly said on Monday it would buy privately-held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash.
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
06:45am, Monday, 27'th Apr 2026
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on i
Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)?
07:05pm, Saturday, 25'th Apr 2026
Eli Lilly is a giant in the weight-loss drug realm, and it's aiming to grow more.
Why Eli Lilly Stock Flopped on Friday
06:30pm, Friday, 24'th Apr 2026
High hopes for a freshly approved drug might not be realized, if early data is any indication.
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1
04:21pm, Friday, 24'th Apr 2026
Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo versus Novo Nordisk's oral Wegovy. LLY's long-term advantage lies in small molecule
